Oculentis Recalls Lentis IOLs in Philippines Due to Reports of Postoperative Opacification

November 10, 2017: By Joan McKenna

1 Ophthalmic NewsBerlin-based Oculentis has issued a voluntary recall in the Philippines for all Lentis intraocular lenses distributed and imported by Ophthaswissmed Philippines, Inc., with an expiration date of January 2017 to May 2020. The Philippines Food and Drug Administration (FDA) issued an advisory Oct. 27.

The agency said Oculentis has received notifications of sporadic late postoperative opacification of the lenses, which may compromise the transparency of the lens over time, potentially leading to reduced visual acuity.

The Philippines FDA said studies by Oculentis indicate that the opacification may be caused by phosphate remnants from a cleaning agent used in production.

The recall covers the Lentis (MDR-04652), Lentis Comfort (MDR-04654), Lentis T Plus (MDR-04647), Lentis T Plus X (MDR-04707), Lentis Comfort Toric (MDR-04708), Lentis M Plus (MDR-04651), Lentis M Plus X (MDR-04653), Lentis M Plus Toric (MDR-04719), and the Lentis M Plus X Toric (MDR-04706).

Oculentis says Lentis IOLs with an expiration of June 2020 or later are unaffected.

The recall notice did not specify whether lenses in other countries are affected or other regulatory bodies have been notified. Oculentis did not respond to a request for additional information.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023